AstraZeneca

Commercial

OFHS250038

The aim of our study is to build on our understanding of head and neck cancer in the UK by using the data from "Our Future Health." We have structured the research into three key objectives: 1. Characterize patient profiles. We will analyze the demographic factors—including age, gender, and family history—alongside clinical features and genetic profiles of individuals diagnosed with head and neck cancer, aiming to identify key characteristics associated with the disease. 2. Identify treatment patterns. We will evaluate the range of treatments patients are receiving, such as surgeries, radiation, and systemic therapies, with the goal of uncovering patterns, gaps, and variations. 3. Investigate determinants of differentiation in disease outcomes. We will explore how the factors identified in Objectives 1 and 2 contribute to variations in disease progression, enhancing our understanding of the reasons behind different patient prognoses. By achieving these objectives, we aim to improve the understanding and management of head and neck cancer, ultimately contributing to the development of enhanced healthcare strategies and personalized treatment approaches in the future. Head and neck cancers are a complex group of diseases with diverse causes and outcomes. Although immunotherapy has demonstrated potential in improving patient outcomes, there are still significant gaps in understanding which real-world patients benefit most from these therapies and how they progress over time. Additionally, limited information exists on the influence of genetic differences and the impact of newer targeted therapies on clinical outcomes. This study aims to add real-world evidence to the head and neck community by analyzing data from the "Our Future Health" program, which includes participants from across the UK. By examining clinical outcomes with treatment and patient characteristics, we aim to identify patterns in how head and neck cancer and the existing treatments affect different groups of people. This can help tailor treatments to individual patients, ensuring they receive the most effective therapy. In addition, this study can identify gaps that could guide future drug development.

Head and neck cancers are a significant health issue affecting thousands of people every year. These cancers often have poor prognosis and impact essential functions such as speaking, breathing, and eating, which greatly affect a person's quality of life. Despite advances in treatment, there remains an unmet need in understanding which patients benefit the most from newer therapies like immunotherapy and targeted treatments. Many patients continue to experience poor outcomes, highlighting the urgent need for more effective, personalized approaches to treatment. Examples of expected benefits include personalized treatment plans, improved patient outcomes and guided drug development. This research not only aims to advance our understanding of head and neck cancers but also strives to translate these findings into actionable strategies that could benefit patients in the UK and the broader head and neck cancer community.

Public Health Research

09/10/2025

09/10/2025

TRE